Updates in diagnosis and treatment of pediatric antiphospholipid syndrome

Curr Rheumatol Rep. 2024 Oct;26(10):366-374. doi: 10.1007/s11926-024-01156-7. Epub 2024 Jul 24.

Abstract

Purpose of review: This review offers an overview of the most important recent articles on pediatric APS.

Recent findings: Non-thrombotic extra criteria manifestations were prevalent in pediatric APS. Pregnancy morbidity has been described as the first manifestation of APS at youth age, impairing gestational outcomes. The 2023 APS criteria were developed for adult APS patients, and there is still a lack of pediatric-specific APS criteria. Catastrophic APS was more commonly reported as the initial manifestation of pediatric APS than in adults. Regarding treatment, direct oral anticoagulants have been recently approval for pediatric patients with venous thrombosis. New approaches have been proposed for severe cases, for arterial thrombosis, and rituximab for refractory cases. Recurrences typically occurred early and were associated with older age at diagnosis. Current studies highlighted the multifaceted nature of pediatric APS. Further large prospective multicenter studies evaluating new medications capable of reducing recurrence risk and improving prognosis in this population will be required.

Keywords: Antiphospholipid syndrome; Childhood; Classification criteria; Prognosis; Systemic Lupus Erythematosus; Treatment.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / complications
  • Antiphospholipid Syndrome* / diagnosis
  • Antiphospholipid Syndrome* / drug therapy
  • Child
  • Female
  • Humans
  • Pregnancy
  • Rituximab / therapeutic use

Substances

  • Anticoagulants
  • Rituximab